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Abstract: Objectives: Few previous studies have assessed the effects of concomitant administration
of multiple potentially psychoactive nutrients. Methods: 95 healthy adult participants consumed
either a nutrient enriched breakfast bar (containing α-Linolenic acid, L-tyrosine, L-theanine, vitamins,
minerals and 21.5 mg of caffeine) or an isocaloric, macronutrient matched control bar for 56 days.
Cognitive function and mood were assessed pre-dose and at 40- and 160-min post-dose on the 1st
and 56th day of the intervention period. Results: The results demonstrated acute effects of treatment
across post-dose assessments on both assessment days in terms of alertness, and on tasks assessing
attention, working and episodic memory and executive function, including cognitively demanding
Serial subtraction and Rapid Visual Information Processing tasks. There were no evident chronic
effects independent of the breakfast bars’ acute effects. Discussion: These results demonstrate that
a nutrient enriched breakfast bar with low caffeine content can exert striking beneficial effects on
acute cognitive function and alertness.
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1. Introduction
Optimal brain function requires adequate dietary intakes of a wide range of essential and
non-essential nutrients, including vitamins, minerals, amino-acids and polyunsaturated fatty acids.
However, cross-sectional data suggests that a sizeable minority of the populations of developed countries
exhibit biochemical deficiencies in one or more of these nutrients that would predispose them to specific
or general diseases related to a lack of that nutrient. For instance, in terms of vitamins/minerals alone,
governmental evidence from the UK [1,2] suggests that deficiency/depletion levels for non-elderly adults
are approximately 4% for vitamin C, 5% for vitamin B12 and approximately 66% for vitamin B2. Some
15.5% of females are also deficient in iron (plasma ferritin). It is notable that only a small minority of
adults meet government minimum guidelines for fruit and vegetable and oily fish consumption [2].
These figures are hardly surprising given that governmental intake recommendations (e.g.,
Recommended Dietary Allowance (RDA) and Recommended Dietary Intake (RDI)), which many fail
to achieve from contemporary diets, are generally set at the minimum level required to avoid disease
states in most of the population. Naturally, the optimal level of any nutrient will not merely be the
level that prevents an increased likelihood of disease, suggesting that a considerable proportion of
the populations of developed countries have less than optimal nutritional status. Nutritional status is
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important because epidemiological evidence suggests that greater consumption or higher circulating
levels of a wide range of nutrients are related to improved cognitive function, or an attenuation of
age-related cognitive decline or risk of dementia. For instance, this relationship has been highlighted for
vitamins B6, B9 and B12 [3,4], vitamin C [5,6], vitamin A [6], vitamin E [7], iron [8], caffeine [9], foods rich
in omega-3 polyunsaturated fatty acids (omega-3 PUFAs) [10,11], and polyphenols [12–14]. A similar
relationship is also evident with respect to the general nutrient adequacy of an individual’s diet [9].
Given the above it is not surprising that, conversely, supplementation with several of the above
nutrients over a period of time may benefit psychological functioning. For instance, accumulating evidence
in normal, healthy adults suggests that supplementation with multi-vitamins/minerals can improve
cognitive function, enhancing performance during multi-tasking and on difficult mental arithmetic
tasks, whilst improving aspects of psychological state (e.g., subjective stress, mood, and fatigue) [15–17].
In contrast, the improvements seen in cognitive function (attention, memory and learning) following iron
supplementation appear to depend on initial iron status where those with initially low levels show the
greatest increases [18]. Polyphenols, such as from cocoa [19–21], are reported to improve performance on
cognitive tasks and, extended supplementation of omega-3 is observed to improve mood, verbal fluency
and memory and reaction time [22,23].
A number of key nutrients have also been shown to exert beneficial effects on brain function following
a single dose. The obvious example here is caffeine, which reliably increases alertness/arousal and
the performance of attention tasks [24]. However, other psychoactive nutrients include the tea specific
amino-acid L-theanine; which can improve vigilance (on a rapid processing task), reaction time and working
memory when consumed with caffeine [25] and essential amino-acids such as L-tyrosine; which improve
complex cognitive processes like word association, cognitive flexibility and updating [26–29]. Intriguingly,
evidence also suggests that single doses of vitamins have bioactive properties. For instance a single
dose of vitamin B9, vitamin C, or vitamin E can increase peripheral vasodilation as measured by flow
mediated dilation [30–35] and single doses of calcium [36], calcium combined with vitamin D [37] and
a multi-vitamin/mineral [38] can increase fat oxidation. Of more relevance to the brain, improvements
in attention and semantic memory task performance have been demonstrated following the first dose of
a multivitamin/mineral administered to children [39] and single doses of multi-vitamin/minerals have been
shown to modify regional brain activity [40], cerebro-electrical activity [41] and cerebral blood-flow [38]
using a variety of imaging techniques.
Taken together, these data suggest that many people may be deficient in multiple micronutrients
and other beneficial nutritional compounds, and that this might contribute to aspects of poor health.
Research suggests that cultures which are less likely to access sufficient levels of these compounds from
dietary sources are more likely to supplement their diets to compensate for nutrient shortfalls [42]:
In the US over half of adults consume supplements (predominantly multivitamins, calcium and fish
oils) [43] compared to less than 10% in Mediterranean-diet consuming countries like Spain [44]. As such,
dietary supplementation with a nutrient enriched food designed to provide an adults approximate
daily minimum requirement of a broad range of essential and non-essential nutrients (including
vitamins and minerals, omega-3 PUFAs and amino acids, plus a low dose of caffeine) may benefit
multiple aspects of cognitive function and mood. This approach may offer a viable means of consuming
essential nutrients for those who do not access these from the diet. This randomised, double-blind,
placebo-controlled, parallel groups study therefore investigated the effects of such an intervention on
the first day of supplementation and following 8 weeks administration, in healthy young adults.
2. Materials and Methods
2.1. Design
The study comprised a randomised, double-blind, placebo-controlled, parallel group comparison
of the effects of acute (Day 1) and chronic (Day 56) consumption of a nutrient enriched breakfast bar
in comparison to a macronutrient-matched control bar. Eight weeks was arbitrarily chosen as the
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supplementation period in the absence of any evidence to indicate what an “effective” period of time
would be. The study received ethical approval from the Northumbria University Faculty of Health
and Life Sciences Ethics Committee (reference: RE-HLS-13-131121-528de56935e26; date approved on
6 January 2014) and was conducted according to the Declaration of Helsinki (1975). All participants
gave their written informed consent prior to their inclusion in the study.
2.2. Participants
A total of 105 participants, aged 21 to 40 years, who self-reported themselves to be in good
physical health were initially randomised. Following drop-outs (due to no further interest in the
study) and withdrawals (due to lack of compliance with treatment consumption or adherence to task
completion) the data from a total of 95 participants (48/47 placebo/active) were subsequently entered
into the analysis. See Figure 1 for details of participant dispositions throughout the study. Given the
multiple active ingredients, it was not possible to calculate a sample size which would encompass
all components but approximately N = 50 per group was considered a reasonable number based on
existing research trials in this area.
Figure 1. Flow-diagram showing participant dispositions throughout the study.
The exclusion criteria for the study included: inability to adequately perform the cognitive tasks,
presence or history of any chronic disease, including neurological, developmental and mood disorders
and self-reported sleep disturbance; use of dietary supplements, use of prescribed medications (with
the exception of oral contraceptives, some topical skin treatments and occasional inhaler use); non-use
of caffeine; food allergies; history of alcohol or drug abuse; or smoking. Participants with high blood
pressure (>139/89 mm Hg) or a BMI > 35 and those that were pregnant/lactating were also excluded.
Demographics for the participants entered into the analysis are presented in Table 1.
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Table 1. Demographics of the participants in the two treatment groups.




Education (year) 17.2 17.5
Vegetables (portion/day) 3.5 3.3
Caffeine consumption (mg/day) 133 150
Blood pressure (sys/dia) 122/76 124/77
Heart rate (bpm) 69 69
Weight (Kg) 67.5 70.3
Height (cm) 170.5 170.6
Body mass index 23.2 24.1
There were no significant differences, on any factor, between the two groups (p’s all > 0.05).
2.3. Treatments
Treatments comprised one of two 50 g biscuit bars which were matched in terms of calories
(220 Kcal), dietary fibre (4.7 g), sugars (8.6 g) and protein (9.6 g).
The control breakfast-bar contained white flour, vegetable oil, sugar, almond flavouring and eggs.
The nutrient enriched bar (Cognutria Foods Inc., Novato, CA, USA) contained whole wheat flour,
peanuts, walnuts, almonds, whey protein, almond flour, ground flax meal, coconut flour, eggs, brown
cane sugar, milk chocolate solids, dark cane sugar, cocoa powder, quinoa, ground coconut, coconut oil.
In addition, the following, derived from natural extracts, were added: L-theanine, lysine, vitamins
B6, B9, B12, zinc gluconate, magnesium citrate and caffeine. These ingredients delivered a total of
1.4 mg of vitamin A, 15 mg of vitamin E, 5 mg of vitamin B5, 1.9 mg of vitamin B6, 400 µg of vitamin
B9, 500 µg of vitamin B12, 400 mg of magnesium, 1000 mg of calcium, 0.36 mg of iron, 11 mg of zinc,
1.4 g of omega-3 fatty acids (α-linolenic acid), 279.0 mg of L-tyrosine, 21.5 mg of caffeine, 59.2 mg of
tryptophan, 39.3 mg of choline, 867 mg of lysine, 125 mg of L-theanine, and 7.3 mg of theobromine.
Control and nutrient enriched bars were delivered from the manufacturers identified only
by a code and were boxed and distributed to participants according to the computer-generated
randomisation schedule by a disinterested third party. To ensure that the researchers remained blinded
as to which bar each participant consumed, the participants were asked to refrain from discussing any
aspect of their biscuit with them and the researcher never viewed the biscuits; which were prepared
for participants by a disinterested 3rd party. When required to make a forced choice at the end of
the treatment period, just over half of all participants (60%) guessed the nature of their treatment
correctly (with 49% accuracy in the nutrient enriched condition alone). These figures did not represent
significantly higher than chance performance.
2.4. Cognitive and Mood Measures
Performance was assessed using the Computerised Mental Performance Assessment System
(COMPASS—Northumbria University, Newcastle upon Tyne, UK); a software platform for the
presentation of classic and bespoke computerised cognitive tasks, with fully randomised parallel
versions of each task delivered at each assessment for each individual. Tasks were presented on a laptop
PC with responses made either via a four-button response box, mouse and cursor, the keyboard’s linear
number pad or, for word recall only, pen and paper. The selection of standard, classic, cognitive
tasks were specifically chosen to provide a broad assessment across all cognitive domains, including
episodic memory, working memory, attention and executive function (Figure 2). Similar selections of
tasks have previously been shown to be sensitive to a number of nutritional interventions [23,45–47].
Additionally, the Cognitive Demand Battery elements assessed working memory/executive function
during a prolonged period of sustained cognitive processing. This approach, inculcating high cognitive
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demands for an extended period of time, has been shown to be sensitive to the effects of numerous
nutritional interventions [19,48–51]. The tasks and other components of each assessment are described
below in order of completion. The timelines of each assessment and the cognitive domains that
individual tasks load upon are shown in Figure 2A.
Figure 2. (A) The running order of the individual cognitive assessments. Tasks are shown in order
of completion with approximate timings with on the left the “cognitive domain” assessed by the
task; (B) Testing session timeline for the 1st (Day 1) and 56th (±2 days) day (Day 56) of treatment
consumption. On each day participants arrived at ~8.30 a.m., completed the Depression Anxiety and
Stress Scales (DASS) and one baseline cognitive assessment (as per panel A) and then consumed their
treatment for that day. They then completed further assessments, commencing at 40 min post-dose and
at 160 min post.
2.4.1. Picture Presentation
Fifteen colour photographic images of objects were presented sequentially on screen for the
participant to remember at the rate of 1 every 3 s, with a stimulus duration of one second.
2.4.2. Face Presentation
A set of twelve passport-style photographic images of people were presented sequentially in
a random order to participants. A first and last name was assigned to each photograph and presented
Nutrients 2017, 9, 1332 6 of 21
on the screen underneath the person’s face. Stimulus duration was three seconds, with a one-second
inter-stimulus duration.
2.4.3. Word Presentation
A unique set of fifteen words was presented. Words were selected at random from a large
bank of words (MRC Psycholinguistic Database) matched for word length, frequency, familiarity and
concreteness. Stimulus duration was one second, as was the inter-stimulus duration.
2.4.4. Immediate Word Recall
The participant was allowed 60 s to write down as many of the words that were just presented as
possible. The task was scored for number correct and errors.
2.4.5. Numeric Working Memory
Five random digits from 1–9 were presented sequentially for the participant to hold in memory.
This was followed by a series of 30 probe digits (15 targets and 15 distractors) for which the participant
indicated whether or not it had been in the original series by a simple “yes” or “no” key press. The task
consisted of 3 separate trials. Accuracy and mean reaction time for correct responses were recorded.
2.4.6. Choice Reaction Time
An arrow appeared on the screen pointing to the left or to the right. Participants responded with
a left or right key press corresponding to the direction of the arrow. There was a randomly varying
inter-stimulus interval of between 1 and 3 s for a total of fifty stimuli. Accuracy and mean reaction
time for correct responses were recorded.
2.4.7. Rapid Visual Information Processing (RVIP) Task
During this 5 min task the participants monitored a continuous series of single digits (1–9) for
targets of three consecutive odd or three consecutive even digits. The digits were presented on
the computer screen at the rate of 100 per minute in a pseudo-random order, with the participant
responding to the detection of a target string with a space bar key press. Eight target strings were
presented in each minute. The task was scored for number of correctly identified target strings and
average reaction time for correct detections.
2.4.8. Corsi Blocks Task
In this task nine identical blue squares appeared on screen in non-overlapping random positions.
A set number of blocks changed colour from blue to red in a randomly generated sequence.
The cursor was locked in position until the entire sequence had been presented, at which point
the participants were instructed to repeat the sequence by clicking on the blocks using the mouse
and cursor. The task was repeated five times at each level of difficulty. The sequence span increased
from 4 upwards, until the participant could no longer correctly recall the sequence, resulting in a span
measure of nonverbal working memory, calculated by averaging the level of the last three correctly
completed trials.
2.4.9. Cognitive Demand Battery
In this instance, four repetitions of a 10 min computerised “Cognitive Demand Battery” (total
running time ~40 min) were completed before the delayed components of the episodic memory tasks.
The battery comprises four components: A Serial 3s subtraction task (2 min), Serial 7s subtraction task
(2 min), Rapid Visual Information Processing (RVIP-5 min) and a “mental fatigue” visual analogue scale.
For the serial subtraction tasks, participants subtracted either 3 or 7 consecutively from a randomly
generated number between 800 and 999 for the duration of the task, entering their responses on the
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keyboard’s linear number pad. These tasks were scored for the number of correct subtractions and
the number of errors. The RVIP task was as described above. Following each completion of the
three tasks participants rated their current subjective “mental fatigue” by using the cursor to position
a cross on a visual analogue scale anchored “not at all” and “extremely” at the ends. The Cognitive
Demand Battery has previously been used effectively to investigate the effects of various nutritional
interventions on cognitive performance and mental fatigue during periods of sustained cognitive
processing [19,48–51].
2.4.10. Peg and Ball Task
In this computerized version of the executive function task subjects were presented with two
configurations of three coloured balls (blue, green, red) on three pegs that each hold three balls.
The subjects have to rearrange the balls, moving one ball at a time, from the starting configuration so
that they match the position of the balls in the goal configuration. Subjects randomly completed 5 trials
each which can be solved in 3, 4 and 5 moves respectively. Each trial generates scores for planning
times prior to moving, time to complete and errors.
2.4.11. Delayed Word Recall
The participant was again given 60 s to write down as many of the words presented previously as
possible. Total number of correct responses and errors were recorded.
2.4.12. Delayed Word Recognition
The original 15 words plus 15 distractor words were presented one at a time in a random order.
For each word, the participant indicated whether or not it was included in the original list of words by
pressing appropriate “yes” and “no” keys as quickly as possible. Stimuli remained on screen until
an appropriate response had been made. Accuracy and mean reaction time for correct responses
were recorded.
2.4.13. Delayed Picture Recognition
The original 15 pictures plus 15 distractor pictures were presented one at a time in a randomised
order. For each picture participants indicated whether or not it was recognised as being from the
original series by pressing appropriate “yes” and “no” keys as quickly as possible. Stimuli remained
on screen until an appropriate response had been made. Accuracy and mean reaction time for correct
responses were recorded.
2.4.14. Names-to-Faces Recall
The twelve original photographs presented at the outset were again presented on the screen,
one at a time. Underneath each picture there was a list of 4 different first names and 4 different last
names. For each photograph participants were instructed to choose the first and last name that was
originally presented with the photograph. The numbers of correct responses for first and last names
were recorded and collapsed to give an overall score for this task.
2.4.15. Mood Measures
Two subjective ratings of mood were taken. A computerised version of the 16 Bond-Lader visual
analogue scales was delivered via the COMPASS system prior to the start of each cognitive assessment.
The results were combined to form 3 mood factors: “alert”, “calm” and “content” [52]. Participants
also completed the Depression, Anxiety and Stress Scales (DASS) on arrival on each day. This 42-item
self-report questionnaire requires participants to rate how much each statement of negative emotional
state applied to them during the past week. This measure is designed to assess both current state and
change in state over time [53].
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2.5. Procedure
Participants attended the laboratory on 4 separate occasions (Introductory/screening visit, Practice Day,
Day 1 and Day 56). Testing took place in a suite of testing facilities within the Brain Performance and
Nutrition Research Centre, Northumbria University, with participants visually isolated from each other.
The Introductory visit to the laboratory comprised: briefing on the requirements of the study;
the obtaining of informed consent; collection of demographic data; health screening; and training on
the cognitive and mood measures.
Following the introductory visit participants attended the laboratory in an overnight fasted state
at 8.30 a.m. on three separate occasions (Practice Day, Day 1 and Day 56). The Practice Day was
a full facsimile of the subsequent visits but was conducted solely to familiarise the participants with
the study procedures/assessments, allow for an assessment of the participants ability to adequately
perform the cognitive tasks and mitigate any practice effects. On the Practice Day participants received
a commercially available breakfast bar and the subsequent data were not entered into the analysis.
The assessment procedure on each day was identical: on arrival participants completed the paper
and pencil Depression, Anxiety and Stress Scales (DASS) followed by a computerised cognitive
assessment. Following this they consumed their treatment for that day. Two further cognitive
assessments commenced at 40 and 160 min following consumption of the day’s treatment. The first of
these assessments was designed to coincide with the known bioavailability of several components and
the latter was timed to coincide with the natural decline in cognitive function typically seen in the late
morning. The active study days, Day 1 and Day 56, differed only in that participants consumed their
randomly allocated intervention (“nutrient enriched” or “placebo” breakfast bar) immediately after the
baseline assessment. At the end of Day 1 they also took away a box containing 4 weeks supply of their
daily intervention and a diary sheet to record their consumption of the breakfast bars. After 4 weeks
participants returned to collect a further 28 days’ supply of breakfast bars and confirm continued
compliance with the study procedures and inclusion/exclusion criteria with the researcher. At the end
of Day 56 diary sheets and uneaten bars were scrutinised to confirm compliance. The Timelines and
assessments on Day 1/Day 56 are shown in Figure 2B.
2.6. Statistics
2.6.1. Acute and Acute/Chronic Superimposed
Change from baseline data were calculated for both the 40- and 160-min post-dose assessment on
both Day 1 and Day 56 with reference to the corresponding pre-dose score on each day.
These data for each outcome were entered into three-way (treatment (nutrient enriched/placebo)
× assessment (40/160 min) × day (1/56)) ANOVAs for those tasks that were completed once per
assessment and four-way (treatment × repetition (1–4) × assessment × day) ANOVAs for those tasks
from the Cognitive Demand Battery which were repeated four times per assessment.
By using this model any purely acute effect of treatment would be seen as a significant main effect of
treatment and any acute effect that had been increased or attenuated by chronic supplementation (defined
here as “acute/chronic superimposed”) would be seen as a significant treatment× day interaction. Higher
order interactions would require further interpretation as necessary.
2.6.2. Pure Chronic Effects
Unadjusted data from each outcome from the baseline assessment on Day 1 and Day 56 were
entered into a two-way (treatment × day) ANOVA for those tasks that were completed once per
assessment and a three-way (treatment × repetition × day) ANOVA for those tasks from the Cognitive
Demand Battery which were repeated four times per assessment.
Using this approach any chronic effect of treatment (with no contribution attributable to the
Day 56 dose of treatment) would be evinced as a treatment × day interaction.
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All ANOVA results for individual tasks that evinced a significant treatment related interaction
effect were further explored with Bonferroni adjusted t tests (calculated using MSError from the
ANOVA) comparing data from the two treatments as required. The stated probability values reflect
the Bonferroni adjustment. Given the exploratory nature of the study no further adjustment was made
for the number of outcomes overall.
3. Results
3.1. Acute and Acute/Chronic Superimposed Effects
3.1.1. Individual Cognitive Tasks and Mood Measures
In terms of mood, there was a significant main effect of treatment on Bond-Lader ratings of
“alertness” (F(1, 93) = 8.919, p = 0.004) with consumption of the nutrient enriched treatment associated
with increased alertness across post-dose assessments on Day 1 and Day 56. Means (±SEM) are
depicted graphically in Figure 3, with data from each assessment presented in Table 2.
Figure 3. Effects of the nutrient enriched bars on performance of the tasks and mood scales that were
repeated once per assessment. Data are baseline adjusted (to the day’s pre-treatment score) means
(±SEM). Asterisks represent a significant difference between treatments in terms of main effects of
treatment on the ANOVA or, for those measures that evinced an interaction, from Bonferroni adjusted
post-hoc comparisons. * p < 0.05; ** p < 0.01; *** p < 0.001.
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Table 2. Data from the cognitive tasks with a single repetition during each assessment.
N
Day 1 Day 56
ANOVA









Placebo 48 55.50 2.15 −1.61 1.29 −4.64 1.69 54.59 2.29 0.79 1.58 −2.02 2.00
Tr p = 0.004
Nutrient+ 47 54.20 2.17 4.49 1.31 4.62 1.71 54.72 2.32 3.42 1.60 1.36 2.02
Content
% along VAS
Placebo 48 59.85 1.92 0.49 0.98 −0.78 1.39 61.05 1.96 −0.31 1.03 −0.88 1.49
Nutrient+ 47 61.07 1.94 1.93 0.99 2.59 1.41 60.41 1.98 1.03 1.04 0.72 1.50
Calm
% along VAS
Placebo 48 61.21 1.70 −0.83 1.29 −2.12 1.15 61.91 1.96 −3.08 1.35 −2.15 1.51
Nutrient+ 47 62.33 1.72 −2.23 1.30 0.11 1.16 63.13 1.98 −4.60 1.37 −4.34 1.52
Immediate word recall
number correct
Placebo 48 7.23 0.29 −0.25 0.29 −0.62 0.30 7.71 0.33 −0.55 0.32 −0.65 0.26
Nutrient+ 47 7.51 0.30 −0.62 0.29 −0.55 0.30 7.84 0.33 −0.31 0.32 −0.85 0.27
Immediate word recall errors
Placebo 48 0.35 0.09 0.08 0.12 0.29 0.13 0.40 0.11 0.06 0.14 0.25 0.15
Nutrient+ 47 0.40 0.09 0.19 0.12 0.11 0.14 0.49 0.11 −0.11 0.14 0.09 0.15
Numeric working memory
% correct
Placebo 48 95.72 0.54 −0.37 0.53 −0.33 0.55 95.51 0.61 −1.07 0.64 −0.32 0.63
Tr × Ass p = 0.04
Nutrient+ 47 95.68 0.55 −0.38 0.54 −0.40 0.56 95.93 0.62 0.12 0.65 −1.28 0.64
Numeric working memory
reaction time (msec)
Placebo 48 724.60 21.16 −33.93 11.23 −40.55 12.09 703.96 19.24 −16.01 10.60 −44.00 11.81
Nutrient+ 47 710.97 21.38 −25.55 11.35 −40.75 12.21 711.91 19.44 −24.64 10.71 −41.06 11.93
Choice reaction time
% correct
Placebo 48 95.67 0.46 0.00 0.46 0.33 0.48 95.83 0.44 −0.17 0.46 0.66 0.50
Nutrient+ 46 96.74 0.47 −0.44 0.47 −0.26 0.49 97.13 0.45 −0.31 0.47 −1.53 0.51
Choice reaction time
reaction time (msec)
Placebo 48 387.44 6.81 2.42 5.22 −2.23 5.56 386.11 6.67 10.23 5.26 13.93 5.48
Nutrient+ 46 395.42 6.96 4.47 5.34 −4.07 5.68 398.75 6.81 3.69 5.37 −5.21 5.60
Rapid Visual Inf Processing
% correct
Placebo 44 61.31 2.91 −2.91 1.93 −3.95 1.94 59.26 3.23 −6.16 1.78 −8.43 2.17 Tr p < 0.001
Tr × Ass p = 0.014Nutrient+ 46 58.91 2.84 2.94 1.87 6.47 1.88 56.36 3.16 1.96 1.72 3.91 2.10
Rapid Visual Inf Processing
reaction time (msec)
Placebo 44 470.3 6.51 3.16 5.57 −3.14 5.56 463.8 10.57 −10.10 5.17 −5.28 5.45 Tr p = 0.002
Nutrient+ 46 477.8 6.36 −21.68 5.38 −19.04 5.37 474.3 10.33 −15.98 5.00 −17.45 5.27
Corsi Span span Placebo 48 6.35 0.13 −0.42 0.12 −0.16 0.13 6.22 0.14 −0.06 0.12 −0.06 0.13 Tr p = 0.004
Nutrient+ 47 6.25 0.13 0.16 0.12 0.06 0.13 6.05 0.14 0.16 0.12 0.16 0.13
Peg and Ball
thinking time (msec)
Placebo 48 3049 176.3 −415.5 86.2 −389.6 102.2 2682 170.5 64.8 100.2 −160.9 105.6
Tr × Day p = 0.014
Nutrient+ 47 2586 178.2 −255.3 87.1 −372.5 103.2 2661 172.3 −345.2 101.3 −410.6 106.7
Peg and Ball
completion time (msec)
Placebo 48 7597 260.8 −775.7 150.0 −990.2 173.2 7145 195.5 −100.9 117.0 −469.5 141.1
Nutrient+ 47 7438 263.6 −818.7 151.6 −1034.2 175.1 7070 197.6 −498.0 118.2 −742.3 142.6
Peg and Ball
number of errors
Placebo 48 2.40 0.44 0.48 0.55 0.08 0.56 2.81 0.37 1.33 0.50 0.67 0.51
Tr × Ass p = 0.036
Nutrient+ 47 3.62 0.44 −1.32 0.56 −0.45 0.57 2.23 0.37 0.64 0.50 0.94 0.51
Delayed word recall
number correct
Placebo 47 4.19 0.31 −1.46 0.33 −2.28 0.34 5.25 0.34 −2.21 0.33 −2.36 0.33
Nutrient+ 47 4.69 0.31 −2.38 0.33 −2.14 0.34 5.05 0.34 −1.83 0.33 −2.00 0.33
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Table 2. Cont.
N
Day 1 Day 56
ANOVA







Delayed word recall errors Placebo 47 0.96 0.15 0.70 0.21 0.94 0.23 0.75 0.14 0.68 0.21 0.57 0.20
Tr p = 0.029
Nutrient+ 47 0.83 0.15 0.55 0.21 0.47 0.23 0.92 0.14 −0.02 0.21 0.19 0.20
Name to Face
% correct
Placebo 48 37.50 3.06 −7.20 2.86 −9.47 3.24 47.57 3.37 −7.96 3.70 −11.55 3.12
Nutrient+ 45 36.11 3.16 −4.06 3.04 −6.84 3.44 42.96 3.48 −4.91 3.93 −9.40 3.32
Name to Face
reaction time (msec)
Placebo 48 5427 320.3 −377.7 327.0 −376.0 375.8 5442 221.3 −177.4 207.9 −461.1 214.5
Nutrient+ 45 5514 330.8 −422.7 347.3 −805.7 399.1 5035 228.5 −300.8 220.9 −493.7 227.9
Picture recognition
% correct
Placebo 45 90.59 1.29 −0.37 1.28 −0.22 1.29 94.82 1.05 −5.41 1.23 −5.33 1.24 Tr × Ass p = 0.015
Nutrient+ 47 89.43 1.26 −2.65 1.25 −3.83 1.26 91.12 1.02 −2.96 1.21 −2.98 1.21
Picture recognition
reaction time (msec)
Placebo 45 767.9 16.09 20.48 15.01 18.75 13.54 788.8 17.39 17.79 14.57 −2.63 14.02
Tr p = 0.002
Nutrient+ 47 798.4 15.75 −15.03 14.68 −30.96 13.24 809.6 17.02 −29.32 14.26 −26.74 13.72
Word recognition % correct Placebo 46 74.71 1.42 −1.20 1.41 −4.34 1.46 79.06 1.51 −1.18 1.40 −2.08 1.51
Nutrient+ 44 77.17 1.46 −3.76 1.44 −2.93 1.49 80.23 1.55 −0.99 1.43 −2.27 1.55
Word recognition reaction
time (msec)
Placebo 46 801.2 18.23 −17.48 14.55 −29.54 17.10 786.1 20.86 7.54 18.72 −58.10 21.75
Nutrient+ 44 800.6 18.64 3.45 14.88 −32.04 17.48 780.7 21.33 14.21 19.14 14.35 22.24
Data are means (+SEM, in italics) and comprise raw data from the pre-dose baseline assessment and “change from baseline” (adjusted to the days’ corresponding pre-dose score) data for
the 40 min and 160 min post-dose assessments. Tr = main effect of treatment; Tr × Ass = treatment × assessment interaction; Tr × Day = treatment × day interaction—all from the ANOVA.
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Consumption of the nutrient enriched treatment was also associated with acute improvements
(evinced as a main effect of treatment across Day 1 and Day 56) to tasks across cognitive domains. In terms
of attention, there was a significant main effect of treatment with regards the accuracy of performing
the Rapid Visual Information Processing (RVIP) task (F(1, 87) = 24.74, p < 0.001) with the nutrient
enriched treatment associated with improved accuracy across post-dose assessments on Day 1 and Day 56.
There was also a significant assessment x treatment interaction (F(1, 87) = 6.29, p = 0.014) with regards the
same measure (Figure 3). Reference to the post-hoc comparisons showed that accuracy was improved
during both assessments (40 min (t (87) = 4.65, p < 0.001), 160 min (t (93) = 7.59, p < 0.001)) with the
interaction representing a numerically greater magnitude of improvement during the 160 min assessment.
With regards the speed of performing the RVIP task, there was also a significant main effect of treatment
(F(1, 87) = 10.29, p = 0.002) with the nutrient enriched treatment associated with increased speed across
post-dose assessments on Day 1 and Day 56.
With regard to working memory, there was a significant main effect on the Corsi blocks span
score (F(1, 93) = 8.49, p = 0.004), with the nutrient enriched treatment being associated with improved
working memory capacity across post-dose assessments on Day 1 and Day 56. There was also
a significant assessment × treatment interaction (F(1, 93) = 4.345, p = 0.04) with regards the accuracy of
performing the Numeric Working Memory task. However, reference to comparisons between means
showed that there were no significant differences between treatments at either assessment.
Episodic memory task performance was also improved by the nutrient enriched treatment,
with main effects seen in terms of a reduced number of errors committed on the Delayed Word
Recall task (F(1, 92) = 4.94, p = 0.029) and improved speed of performing the Picture Recognition task
(F(1, 90) = 9.9, p = 0.002) across post-dose assessments on Day 1 and Day 56. However, with regards the
latter task, there was also a significant treatment × day interaction (F(1, 90) = 6.15, p = 0.015) in terms
of accuracy of performance. Reference to the means showed that this effect represented a decrement in
performance on Day 1 (t (93) = 2.44, p < 0.05), with a trend towards improved performance on Day 56
(t (93) = 1.99, p < 0.1).
In terms of executive function, there was a significant treatment × day interaction (F(1, 93) = 6.33,
p = 0.014) on the Peg and Ball task in terms of “thinking time”. Reference to the post-hoc comparisons
showed that participants required a shorter amount of time to plan their moves following consumption
of the nutrient enriched intervention but only on Day 56 (t (93) = 3.57, p < 0.01). However, there was
also significant treatment × assessment interaction (F(1, 93) = 4.55, p = 0.036) with regards the number
of errors committed during the same task. Reference to the post-hoc comparisons suggested that this
effect represented an increased accuracy of performance following the nutrient enriched bar which
was restricted to the 40 min post-dose assessment (t (93) = 2.55, p < 0.05).
Means (±SEM) for the measures from the tasks that were repeated once per assessment and which
evinced a significant treatment related effect are depicted graphically in Figure 3. Means (±SEM) for
each assessment on Day 1 and Day 56 are presented in Table 2.
3.1.2. Cognitive Demand Battery (CDB)
Consumption of the nutrient enriched treatment was associated with acute improvements on all
three tasks within the Cognitive Demand Battery. There was a main effect of treatment; representing
increased correct subtractions following the nutrient enriched bars across post-dose assessments on
Day 1 and Day 56, for both the Serial 3s and Serial 7s tasks (Serial 3s (F(1, 93) = 24.4, p < 0.001);
Serial 7s (F(1, 93) = 13.4, p < 0.001)). There was also a main effect of treatment on both the accuracy
of performing the Rapid Visual Information Processing task; with the nutrient enriched intervention
leading to improvements in accuracy across Day 1 and Day 56 (F(1, 75) = 47.7, p < 0.001) and improved
speed of performance (main treatment effect (F(1, 75) = 8.1, p = 0.006)). As well as these objective
improvements in performance subjective ratings of mental fatigue (measured after each repetition
of the three CDB tasks) was also significantly reduced across Days 1 and 56 following the nutrient
enriched intervention (F(3, 279) = 22.5, p < 0.001).
Nutrients 2017, 9, 1332 13 of 21
Means (±SEM) for the CDB tasks that evinced a significant treatment related effect are depicted
graphically in Figure 4. Data (means ± SEM) from each repetition of the tasks during each assessment
on Day 1 and Day 56 are presented in Table 3.
Figure 4. Effects of the nutrient enriched bars on performance of the Cognitive Demand Battery tasks
that were repeated four times per assessment. Data are baseline adjusted (to the day’s pre-treatment
score) means (±SEM). All of the effects were main effects of treatment across assessments and days.
Asterisks represent a significant difference between treatments in terms of main effects of treatment on
the ANOVA. * p < 0.05; ** p < 0.01; *** p < 0.001.
3.2. Pure Chronic Effects
There were no significant differences in performance for any task during the pre-dose assessment
on Day 56 that would indicate a chronic effect of treatment in the absence of any acute effects.
4. Discussion
The consumption of a nutrient enriched breakfast bar was associated with broad, significant,
acute improvements in cognitive function across all cognitive domains, in comparison to placebo,
on both Day 1 and Day 56 of an 8 weeks treatment regimen. Specifically, significant benefits were
seen in terms of attention (RVIP), episodic memory (Delayed word recall, Picture recognition (speed)),
working memory (Numeric working memory, Corsi Blocks, Serial subtractions) and executive function
(Peg and Ball, Serial subtractions). In addition, subjective alertness and mental fatigue were improved.
The only decrements in performance were seen in terms of a decrease in accuracy on the Picture
recognition task on Day 1, with a trend towards the opposite effect on Day 56.
There was, however, no evidence of a simple chronic effect of 56 days of treatment with the
nutrient enriched bars when the pre-treatment, baseline, performance data on Day 1 and Day 56 were
compared. However, it should be noted that the statistical power of this comparison was somewhat
lower than that of the acute/superimposed analysis and did not benefit from a baseline comparator.
Having said this, the only evidence of differential acute effects between Day 1 and Day 56 which might
represent a chronic/superimposed effect of the intervention was a significant interaction between day
and treatment on the Peg and Ball task thinking time; showing that this measure was enhanced only
on Day 56. Of course, one striking aspect of the current results is that, whilst there was no evidence of
chronic effects, the acute effects of the nutrient enriched intervention was still apparent after 56 days of
daily consumption, with no evidence of habituation to its effects.
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Table 3. Data from the Cognitive Demand Battery tasks that were repeated four times during each assessment.
Pre-Dose Baseline 40 min Post-Dose (Change) 60 min Post-Dose (Change) ANOVA
Sig. EffectsDay Rep 1 Rep 2 Rep 3 Rep 4 Rep 1 Rep 2 Rep 3 Rep 4 Rep 1 Rep 2 Rep 3 Rep 4
RVIP
% correct
Day 1 Plac 63.33 3.34 60.1 3.34 57.92 3.41 55.5 3.65 −4.31 1.92 −3.82 1.81 −3.33 1.77 −2.50 2.38 −4.44 1.95 −5.76 1.96 −5.63 2.12 0.35 2.08
Treatment p
< 0.001
Nut+ 60.18 3.13 58.7 3.13 56.10 3.20 52.8 3.42 3.35 1.80 5.30 1.70 6.28 1.66 7.44 2.23 4.27 1.82 −0.55 1.84 0.73 1.98 3.90 1.95
Day 56 Plac 59.17 3.28 54.4 3.38 54.31 3.63 51.1 3.36 −7.08 2.11 −2.22 1.91 −7.36 2.04 −2.01 2.24 −6.67 1.92 −4.83 2.13 −3.82 1.99 −3.54 2.44




Day 1 Plac 489.54 8.75 489 8.32 490 8.89 495 7.99 −3.07 6.22 −8.94 5.83 −11.7 6.74 −7.21 6.20 −9.49 6.44 −17.8 5.64 −12.8 6.46 −9.38 7.15
Treatment p
< 0.006
Nut+ 486.76 8.20 483 7.80 483 8.33 483 7.49 −16.2 5.83 −18.3 5.46 −12.7 6.32 −7.7 5.81 −20.8 6.04 −17.8 5.29 −13.5 6.06 −8.32 6.70
Day 56 Plac 486.55 7.84 486 8.48 491 8.37 495 7.65 0.05 5.36 −1.91 5.48 3.20 6.35 −8.26 6.65 −10.3 5.94 −6.47 5.22 −3.93 6.70 −17.4 7.14
Nut+ 488.00 7.34 497 7.95 502 7.84 493 7.17 −13.3 5.02 −23.5 5.14 −28.3 5.95 −14.6 6.23 −19.5 5.57 −29.6 4.89 −19.6 6.27 −17.9 6.69
RVIP
False alarms
Day 1 Plac 0.81 0.16 0.81 0.15 0.92 0.18 0.78 0.14 −0.08 0.16 0.10 0.20 −0.08 0.18 −0.08 0.16 −0.06 0.18 0.00 0.19 −0.28 0.21 −0.19 0.18
Treatment p
< 0.005
Nut+ 0.42 0.15 0.46 0.14 0.34 0.17 0.34 0.13 0.24 0.15 0.15 0.19 0.02 0.17 0.27 0.15 0.17 0.17 0.37 0.18 0.37 0.20 0.49 0.17
Day 56 Plac 0.92 0.18 0.83 0.14 0.78 0.15 0.69 0.14 −0.03 0.21 −0.08 0.19 −0.08 0.24 −0.14 0.20 −0.28 0.21 −0.28 0.15 −0.14 0.18 0.22 0.18
Nut+ 0.73 0.17 0.56 0.13 0.56 0.14 0.59 0.13 −0.12 0.20 0.07 0.17 0.27 0.22 0.15 0.18 −0.05 0.20 0.00 0.14 0.07 0.16 −0.05 0.17
Serial 3s
Number correct
Day 1 Plac 44.60 2.17 46.42 2.20 45.69 2.03 44.90 2.18 4.71 1.00 1.46 1.04 1.60 1.07 3.06 1.09 3.60 1.10 1.46 1.04 3.15 1.30 1.52 1.25
Treatment p
< 0.001
Nut+ 46.68 2.20 49.30 2.22 47.77 2.05 48.70 2.20 7.60 1.01 3.94 1.05 5.28 1.08 5.02 1.10 7.09 1.11 4.45 1.05 4.36 1.31 4.34 1.26
Day 56 Plac 43.48 2.40 47.65 2.28 45.73 2.30 45.58 2.36 6.48 1.52 2.06 1.27 3.33 1.11 −0.79 1.38 7.90 1.64 1.81 1.16 3.15 1.40 2.46 1.31
Nut+ 45.75 2.42 48.11 2.31 48.49 2.32 48.38 2.39 9.85 1.54 7.74 1.28 6.15 1.12 5.13 1.39 11.30 1.66 5.26 1.17 5.81 1.41 6.28 1.32
Serial 3s
Number of errors
Day 1 Plac 2.15 0.30 2.06 0.37 2.42 0.33 2.50 0.38 0.73 0.44 0.63 0.46 0.02 0.42 0.00 0.40 0.42 0.37 0.69 0.38 0.19 0.39 0.29 0.49
Nut+ 2.77 0.30 2.64 0.38 2.72 0.33 2.72 0.39 0.00 0.45 0.15 0.46 0.11 0.42 0.28 0.41 −0.13 0.37 −0.26 0.38 −0.68 0.40 −0.11 0.50
Day 56 Plac 2.96 0.37 2.46 0.35 2.67 0.36 2.56 0.35 0.63 0.47 0.19 0.37 −0.17 0.46 0.58 0.47 −0.06 0.47 −0.17 0.39 −0.33 0.39 −0.19 0.43
Nut+ 2.30 0.37 2.45 0.35 2.36 0.36 2.57 0.35 0.94 0.47 −0.30 0.38 0.55 0.47 0.40 0.48 0.49 0.47 0.38 0.39 −0.02 0.40 −0.15 0.44
Serial 7s
number correct
Day 1 Plac 25.94 1.51 26.42 1.52 26.81 1.58 26.40 1.53 2.83 0.75 2.38 0.79 1.56 0.84 1.58 0.79 2.50 0.79 2.90 0.88 3.17 0.88 3.92 0.81
Treatment p
< 0.001
Nut+ 28.00 1.53 28.43 1.53 29.40 1.60 29.64 1.55 4.68 0.76 4.00 0.80 4.21 0.85 4.06 0.80 5.87 0.80 4.40 0.89 3.49 0.89 3.83 0.82
Day 56 Plac 26.58 1.48 26.17 1.57 26.98 1.50 27.15 1.61 2.25 0.88 2.52 0.91 1.21 0.91 1.13 1.06 4.33 0.97 4.10 1.09 2.92 0.90 2.54 0.95
Nut+ 27.96 1.50 29.53 1.59 29.92 1.52 28.51 1.62 5.21 0.89 3.62 0.92 3.11 0.91 4.68 1.07 7.23 0.98 4.89 1.10 3.79 0.91 5.30 0.96
Serial 7s
number of errors
Day 1 Plac 2.25 0.34 2.33 0.34 2.71 0.35 2.31 0.37 0.94 0.44 0.10 0.43 0.38 0.42 0.69 0.46 0.75 0.36 0.60 0.42 −0.17 0.43 0.50 0.42
Nut+ 2.26 0.35 2.81 0.35 2.89 0.35 3.21 0.38 0.70 0.45 0.68 0.44 0.23 0.43 −0.26 0.46 0.32 0.36 −0.32 0.43 0.38 0.44 0.17 0.42
Day 56 Plac 2.44 0.32 2.69 0.34 2.50 0.30 2.83 0.40 0.88 0.35 −0.10 0.41 0.83 0.40 0.15 0.40 0.31 0.35 −0.27 0.39 0.58 0.35 0.23 0.41
Nut+ 2.32 0.32 2.62 0.34 2.92 0.30 3.75 0.41 0.79 0.35 0.04 0.41 0.09 0.41 −0.53 0.41 0.38 0.36 0.53 0.39 0.02 0.35 −0.87 0.41
Fatigue
% along VAS
Day 1 Plac 56.29 2.48 59.35 2.80 62.29 2.84 65.08 2.93 3.81 2.42 6.58 2.27 5.19 2.36 3.90 2.16 8.40 2.43 10.48 2.22 10.04 2.14 7.10 1.90
Treatment p
< 0.001
Nut+ 57.89 2.51 62.83 2.83 67.38 2.87 70.45 2.96 −5.60 2.44 −7.09 2.30 −8.96 2.39 −11.5 2.18 −1.43 2.45 0.79 2.24 0.94 2.16 −0.28 1.92
Day 56 Plac 51.88 2.51 58.73 2.46 63.31 2.55 66.25 2.72 8.10 2.40 6.19 2.19 4.79 2.05 3.85 1.97 10.67 2.47 9.71 2.31 5.15 2.39 3.90 2.27
Nut+ 57.87 2.53 65.45 2.49 70.47 2.57 74.87 2.75 −0.98 2.42 −3.40 2.21 −4.53 2.07 −6.28 1.99 5.17 2.50 3.49 2.34 1.53 2.41 −1.28 2.30
Data are means (±SEM, in italics) and comprise raw data from the pre-dose baseline assessment and “change from baseline” (adjusted to the days’ corresponding pre-dose score) data for
the 40 min and 160 min post-dose assessments. Sample sizes were 77 (placebo 36) for the Rapid Visual Information Processing task (RVIP) and 95 (placebo 48) for the Serial 3s, 7s and
fatigue. Treatment = main effect of treatment from the ANOVA; Plac = placebo; Nut+ = nutrient enriched; RVIP = Rapid Visual Information Processing task; Rep = repetition of task.
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Clearly, the demonstration of such pronounced benefits to cognitive function/mood raises the
question of which component(s) are responsible. It is always tempting to single out caffeine, where it
is present, as the major psychoactive component of any multi-ingredient intervention. However,
this seems unlikely here for several reasons. The first is that the daily nutrient enriched intervention
contained a low dose of 21.5 mg of caffeine, which equates to less than the caffeine in half a cup
of tea and approximately a fifth of that present in a cup of filter coffee. Whilst a dose as low as
12.5 mg caffeine has been shown to exert some limited cognitive effects in a single study [54], the dose
administered here was well below the typical psychoactive doses (75–200+ mg) employed in caffeine
research. Whilst there has been little research assessing dose-responses to caffeine, it has previously
been shown [55] that a 50 mg dose of caffeine increased subjective alertness but did not engender the
beneficial effects on cognitive function and other aspects of mood, associated with two higher doses
(150 mg and 450 mg) of caffeine. The second is that the effects seen here are also far more comprehensive
than caffeine’s typical effects, which are generally restricted to increased alertness/arousal and
improvements restricted to relatively simple attention/vigilance tasks. Caffeine does not usually
have any effect on long-term (episodic) memory tasks and has inconsistent effects on working memory
tasks; with evidence suggesting that it impairs the performance of more complex tasks [24,56,57].
With regards the working memory tasks utilized here, two previous experiments using the same
Cognitive Demand Battery demonstrated that 33 mg, 38 mg and 46 mg of caffeine could improve
performance on the RVIP but only in terms of accuracy of performance, with no improvements seen
in terms of speed of performance of the RVIP or on the Serial 3s and Serial 7s tasks [51]. The serial
subtraction tasks could best be described as complex, working memory/executive function tasks and
caffeine would therefore not be expected to have an impact. Importantly, performance on both of these
serial subtraction tasks was improved in the current study following consumption of the nutrient
enriched bars, alongside improvements in both speed and accuracy of the RVIP task.
Naturally, this raises the question of which non-caffeine components might have been responsible
for the striking findings here? The general assumption that vitamins and minerals have to be
administered over weeks or months to have any physiological effect is not based on scientific evidence.
Few studies have assessed the acute effects of micronutrients but, from those studies that have, there
is good evidence to suggest that vitamins/minerals have physiological and brain function effects
following a single dose [4]. For instance, single doses of vitamins B9, C, E and C/E combined have all
been shown to increase vasodilation, as measured by peripheral flow mediated dilation, in groups
with disease-related or experimentally induced endothelial dysfunction [30–35]. Similarly, single doses
of calcium [36], calcium combined with vitamin D [37] and a multi-vitamin/mineral [38] have been
shown to increase fat oxidation and, for the multivitamin/mineral, overall energy expenditure [38] as
measured from exhaled pulmonary gas using Indirect Calorimetry.
Naturally, any intervention that has an impact on metabolism or blood-flow will also inevitably
have an impact on the brain; this being the most metabolically active organ in the body. More direct
evidence of acute brain function effects of micronutrients include the demonstration of improvements
in attention and semantic memory task performance following the first dose of a multivitamin/mineral
administered to children [39] and modulation of regional brain activity during a task measuring
focussed attention, as measured with fMRI [40] and cerebro-electrical activity (EEG-steady state
visually evoked potentials) during an attention task [41] following a multi-vitamin/mineral. A recent
study [38] also demonstrated increased cerebral blood-flow in the frontal cortex during task
performance following a single dose of a multivitamin/mineral.
Beyond vitamins and minerals, the nutrient enriched bars also contained several other components
that could plausibly have had an acute impact on performance. For instance, oral administration of
high (~7–21 g) single doses of the amino-acid L-tyrosine, the direct precursor to the catecholamine
neurotransmitters and trace amines, have been consistently shown to attenuate the cognitive and
mood decrements associated with a range of stressors (e.g., sleep deprivation, cold, noise, physical and
psychological stress) in humans [57–65]. More recent research has also shown that lower, single doses
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of 2 g of L-tyrosine can improve cognitive function in the absence of stressors [26–29], with some
evidence that these effects are stronger for more cognitively demanding tasks [29,66]. Whilst a lower
dose (279 mg) of L-tyrosine was administered here, there is, to date, no evidence that lower doses such
as this would not be equally effective, and no data relating to the interactive effects of L-tyrosine and the
other essential amino acids administered here (L-tryptophan (60 mg) and lysine (860 mg)). It may be
relevant that the nutrient enriched bars also contained other components that have been shown to have
acute beneficial effects on cognitive function, including whey protein [67,68] and cocoa-flavonols [19],
although the quantities administered here were somewhat less than those investigated previously.
One further explanation of the striking improvements in cognitive function, alertness and mental
fatigue seen here could be that the low dose of caffeine has evinced an interactive or synergistic
effect with one or more of the many other potentially bioactive ingredients in the nutrient enriched
product. A comparatively small but growing body of research suggests that caffeine’s effects are
typically modulated by the presence of other bioactive components and vice versa. The most obvious
example here is the differential effects of coffee and tea on psychological functioning which are
mediated by both the varying caffeine levels and the presence, or not, of L-theanine [69]. This amino
acid was present at 125 mg in the nutrient enriched bar, equivalent to the amount found in 5 cups
of tea [70]. This tea-specific amino-acid has been shown to potentiate the effects of caffeine on
cognitive function and mood [25] and abolish caffeine’s negative effects in terms of increased blood
pressure [71] and decreased cerebral blood-flow [70]. Similarly, the co-administration of the amino
acids taurine [72,73] and L-ornithine [74], the non-caffeine phytochemicals present in guarana [75],
vitamins [40,41], glucose [76,77] and ephedrine [78] have also been shown to interact with caffeine
with regards brain function. One final potential factor that might have had an impact on the results
here may be the lengthy cognitive assessment and the resultant inculcation of mental fatigue. This may
well have contributed to the pattern of results—indeed, the Cognitive Demand Battery is specifically
designed to fatigue participants in order to provide a sensitive milieu for any treatment related effects.
However, the pattern of cognitive improvements seen here included improvements to the performance
of tasks from across the assessment, rather than just towards the later stages, suggesting that any
improvements were not overly dependent on the participants’ level of mental fatigue.
Whilst the results here did not demonstrate any specific chronic effects of 8 weeks supplementation,
this does not preclude the possibility that extended consumption of a nutrient enriched food such as
this will have long term consequences for brain function. As an example, the nutrient enriched bars
contained 1.4 g of omega-3 PUFAs, in the form of α-linolenic acid derived from the flax meal and
walnut components. α-Linolenic acid can provide an important source of other bioactive omega-3
fatty acids such as EPA and DHA in the large proportion of the population that have no intake,
or low intake, of these PUFAs. The mechanisms of action of omega-3 PUFAs are typically thought
to relate to DHA’s role as a major component of the membrane phospholipids in the brain as well as
its multifarious contributions to neural membrane structural properties and functions. Alternatively,
the role of eicosanoid and docosanoid omega-3 PUFA derivatives as cellular mediators of inflammation,
immune function, oxidative damage and vascular responses [10] are also thought to be key. Both of
these mechanisms would become more relevant as the supplementation period continued. In line with
this, whilst 3 months administration of omega-3 PUFAs has been shown to have no effect on cognitive
function in healthy adults [79,80], 6 months administration did result in improved memory and attention
task performance [23]. Interestingly, 3 months administration of DHA did increase haemodynamic
responses in the prefrontal cortex during tasks but failed to result in performance or mood benefits [81,82].
A similar argument can also be made for the potential chronic effects of micronutrients; specifically, if their
mechanisms of action involve the mitigation of, for instance, ongoing oxidative stress or homocysteine
related neuronal damage, then their effects will only become apparent following a relatively long
supplementation period.
Nutrients 2017, 9, 1332 17 of 21
5. Conclusions
In conclusion, a nutrient enriched breakfast bar, which contained potentially bioactive levels
of vitamins/minerals, omega-3 PUFAs, amino acids, including L-theanine and caffeine, resulted
in broad acute improvements in cognitive function and alertness that were sustained even after
56 days administration.
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